α-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children

L. Mitchell, F. Piovella, F. Ofosu, M. Andrew

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Antithrombin III (ATIII) deficiency has been implicated in adults as a predisposing factor to thrombosis; however, thromboembolic complications are rare in children with the same deficiency. We hypothesized that because of the elevated levels of plasma α-2-macroglobulin (α2M) throughout childhood, plasmas of ATIII-deficient children inhibit thrombin more efficiently than those of ATIII-deficient adults. In total, 14 ATIII-deficient adults (ages 25 to 46 years), 13 ATIII-deficient children (ages 2 to 13 years), 9 normal children (ages 3 to 15 years), and 16 normal adults were studied. We measured thrombin inhibition in these plasmas, as well as the contributions of ATIII, α2M, and heparin cofactor II (HCII) as thrombin inhibitors in each plasma. 125I-α-thrombin, 25 nmol/L, was added to each plasma (defibrinated with Arvin at 37°C), and 90 seconds later the free thrombin and thrombin-inhibitor complexes were quantitated after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, autoradiography, and densitometric scanning. Plasma from ATIII-deficient adults inhibited significantly less thrombin (12.8 ± 0.6 nmol/L) than both normal adults (16.1 ± 0.3 nmol/L, P <.01), normal children (15.7 ± 0.4 nmol/L, P <.01), or ATIII-deficient children (15.5 ± 0.3 nmol/L, P <.01). There was no significant difference between the total concentration of thrombin inhibited by ATIII-deficient children and either normal adult or normal children groups. In addition, plasmas of ATIII-deficient children inhibited thrombin significantly more efficiently than plasma of ATIII-deficient adults (P <.01). In the ATIII-deficient patients there was a significant correlation between the α2M level and ability to inhibit thrombin (P <.01), but no correlation between either ATIII or HCII levels and thrombin inhibition. On the addition of heparin (0.4 U/mL) to plasma, all four types of plasma inhibited thrombin to the same extent. Although ATIII was the predominant inhibitor in all heparinized plasmas, HCII inhibited more thrombin in the ATIII-deficient patients than in normal patients (2.8 ± 0.3 v 1.2 ± 0.2 nmol/L, P <.01). We hypothesize that the lower risk of thromboembolic complications in ATIII-deficient children may be due in part to the protective effect of elevated α2M levels during childhood.

Original languageEnglish
Pages (from-to)2299-2304
Number of pages6
JournalBlood
Volume78
Issue number9
Publication statusPublished - Nov 1 1991

Fingerprint

Macroglobulins
Antithrombin III
Thrombin
Plasmas
Heparin Cofactor II
Ancrod
Antithrombin III Deficiency
Autoradiography
Sodium Dodecyl Sulfate
Causality
Electrophoresis

ASJC Scopus subject areas

  • Hematology

Cite this

α-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. / Mitchell, L.; Piovella, F.; Ofosu, F.; Andrew, M.

In: Blood, Vol. 78, No. 9, 01.11.1991, p. 2299-2304.

Research output: Contribution to journalArticle

Mitchell, L. ; Piovella, F. ; Ofosu, F. ; Andrew, M. / α-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children. In: Blood. 1991 ; Vol. 78, No. 9. pp. 2299-2304.
@article{11d97f364b704ba7849e7243b9b3f9d4,
title = "α-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children",
abstract = "Antithrombin III (ATIII) deficiency has been implicated in adults as a predisposing factor to thrombosis; however, thromboembolic complications are rare in children with the same deficiency. We hypothesized that because of the elevated levels of plasma α-2-macroglobulin (α2M) throughout childhood, plasmas of ATIII-deficient children inhibit thrombin more efficiently than those of ATIII-deficient adults. In total, 14 ATIII-deficient adults (ages 25 to 46 years), 13 ATIII-deficient children (ages 2 to 13 years), 9 normal children (ages 3 to 15 years), and 16 normal adults were studied. We measured thrombin inhibition in these plasmas, as well as the contributions of ATIII, α2M, and heparin cofactor II (HCII) as thrombin inhibitors in each plasma. 125I-α-thrombin, 25 nmol/L, was added to each plasma (defibrinated with Arvin at 37°C), and 90 seconds later the free thrombin and thrombin-inhibitor complexes were quantitated after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, autoradiography, and densitometric scanning. Plasma from ATIII-deficient adults inhibited significantly less thrombin (12.8 ± 0.6 nmol/L) than both normal adults (16.1 ± 0.3 nmol/L, P <.01), normal children (15.7 ± 0.4 nmol/L, P <.01), or ATIII-deficient children (15.5 ± 0.3 nmol/L, P <.01). There was no significant difference between the total concentration of thrombin inhibited by ATIII-deficient children and either normal adult or normal children groups. In addition, plasmas of ATIII-deficient children inhibited thrombin significantly more efficiently than plasma of ATIII-deficient adults (P <.01). In the ATIII-deficient patients there was a significant correlation between the α2M level and ability to inhibit thrombin (P <.01), but no correlation between either ATIII or HCII levels and thrombin inhibition. On the addition of heparin (0.4 U/mL) to plasma, all four types of plasma inhibited thrombin to the same extent. Although ATIII was the predominant inhibitor in all heparinized plasmas, HCII inhibited more thrombin in the ATIII-deficient patients than in normal patients (2.8 ± 0.3 v 1.2 ± 0.2 nmol/L, P <.01). We hypothesize that the lower risk of thromboembolic complications in ATIII-deficient children may be due in part to the protective effect of elevated α2M levels during childhood.",
author = "L. Mitchell and F. Piovella and F. Ofosu and M. Andrew",
year = "1991",
month = "11",
day = "1",
language = "English",
volume = "78",
pages = "2299--2304",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

TY - JOUR

T1 - α-2-macroglobulin may provide protection from thromboembolic events in antithrombin III-deficient children

AU - Mitchell, L.

AU - Piovella, F.

AU - Ofosu, F.

AU - Andrew, M.

PY - 1991/11/1

Y1 - 1991/11/1

N2 - Antithrombin III (ATIII) deficiency has been implicated in adults as a predisposing factor to thrombosis; however, thromboembolic complications are rare in children with the same deficiency. We hypothesized that because of the elevated levels of plasma α-2-macroglobulin (α2M) throughout childhood, plasmas of ATIII-deficient children inhibit thrombin more efficiently than those of ATIII-deficient adults. In total, 14 ATIII-deficient adults (ages 25 to 46 years), 13 ATIII-deficient children (ages 2 to 13 years), 9 normal children (ages 3 to 15 years), and 16 normal adults were studied. We measured thrombin inhibition in these plasmas, as well as the contributions of ATIII, α2M, and heparin cofactor II (HCII) as thrombin inhibitors in each plasma. 125I-α-thrombin, 25 nmol/L, was added to each plasma (defibrinated with Arvin at 37°C), and 90 seconds later the free thrombin and thrombin-inhibitor complexes were quantitated after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, autoradiography, and densitometric scanning. Plasma from ATIII-deficient adults inhibited significantly less thrombin (12.8 ± 0.6 nmol/L) than both normal adults (16.1 ± 0.3 nmol/L, P <.01), normal children (15.7 ± 0.4 nmol/L, P <.01), or ATIII-deficient children (15.5 ± 0.3 nmol/L, P <.01). There was no significant difference between the total concentration of thrombin inhibited by ATIII-deficient children and either normal adult or normal children groups. In addition, plasmas of ATIII-deficient children inhibited thrombin significantly more efficiently than plasma of ATIII-deficient adults (P <.01). In the ATIII-deficient patients there was a significant correlation between the α2M level and ability to inhibit thrombin (P <.01), but no correlation between either ATIII or HCII levels and thrombin inhibition. On the addition of heparin (0.4 U/mL) to plasma, all four types of plasma inhibited thrombin to the same extent. Although ATIII was the predominant inhibitor in all heparinized plasmas, HCII inhibited more thrombin in the ATIII-deficient patients than in normal patients (2.8 ± 0.3 v 1.2 ± 0.2 nmol/L, P <.01). We hypothesize that the lower risk of thromboembolic complications in ATIII-deficient children may be due in part to the protective effect of elevated α2M levels during childhood.

AB - Antithrombin III (ATIII) deficiency has been implicated in adults as a predisposing factor to thrombosis; however, thromboembolic complications are rare in children with the same deficiency. We hypothesized that because of the elevated levels of plasma α-2-macroglobulin (α2M) throughout childhood, plasmas of ATIII-deficient children inhibit thrombin more efficiently than those of ATIII-deficient adults. In total, 14 ATIII-deficient adults (ages 25 to 46 years), 13 ATIII-deficient children (ages 2 to 13 years), 9 normal children (ages 3 to 15 years), and 16 normal adults were studied. We measured thrombin inhibition in these plasmas, as well as the contributions of ATIII, α2M, and heparin cofactor II (HCII) as thrombin inhibitors in each plasma. 125I-α-thrombin, 25 nmol/L, was added to each plasma (defibrinated with Arvin at 37°C), and 90 seconds later the free thrombin and thrombin-inhibitor complexes were quantitated after sodium dodecyl sulfate-polyacrylamide gel electrophoresis, autoradiography, and densitometric scanning. Plasma from ATIII-deficient adults inhibited significantly less thrombin (12.8 ± 0.6 nmol/L) than both normal adults (16.1 ± 0.3 nmol/L, P <.01), normal children (15.7 ± 0.4 nmol/L, P <.01), or ATIII-deficient children (15.5 ± 0.3 nmol/L, P <.01). There was no significant difference between the total concentration of thrombin inhibited by ATIII-deficient children and either normal adult or normal children groups. In addition, plasmas of ATIII-deficient children inhibited thrombin significantly more efficiently than plasma of ATIII-deficient adults (P <.01). In the ATIII-deficient patients there was a significant correlation between the α2M level and ability to inhibit thrombin (P <.01), but no correlation between either ATIII or HCII levels and thrombin inhibition. On the addition of heparin (0.4 U/mL) to plasma, all four types of plasma inhibited thrombin to the same extent. Although ATIII was the predominant inhibitor in all heparinized plasmas, HCII inhibited more thrombin in the ATIII-deficient patients than in normal patients (2.8 ± 0.3 v 1.2 ± 0.2 nmol/L, P <.01). We hypothesize that the lower risk of thromboembolic complications in ATIII-deficient children may be due in part to the protective effect of elevated α2M levels during childhood.

UR - http://www.scopus.com/inward/record.url?scp=0025941122&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025941122&partnerID=8YFLogxK

M3 - Article

C2 - 1718494

AN - SCOPUS:0025941122

VL - 78

SP - 2299

EP - 2304

JO - Blood

JF - Blood

SN - 0006-4971

IS - 9

ER -